🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

RecruitingPhase 2, Phase 3Ages 18 Years - 75 YearsAllGuangzhou Virotech Pharmaceutical Co., Ltd.
NCT07589244 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures. * Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender. * Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition). * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Have an anticipated life expectancy of ≥ 3 months. * Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities. Exclusion Criteria: * Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies. * Receipt of other unapproved investigational drugs/devices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status. * History of splenectomy. * Pregnant or breastfeeding women.
💊

What it tests

  • VRT106
  • VRT106 in combination with camrelizumab and apatinib
  • Investigator's Choice of Standard of Care
📍

Where

1 site
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy